TherapeuticsMD (TXMD) Misses Q2 EPS by 5c
Get Alerts TXMD Hot Sheet
Join SI Premium – FREE
TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.65 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Torrid Holdings Inc. (CURV) Tops Q4 EPS by 4c, provides guidance
- NaaS Technology Inc. (NAAS) Reports Q1 Loss of $0.29
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!